Alpha Tau Medical Ltd. (DRTS) News
Track canonical SquawkNews coverage tagged to DRTS, Alpha Tau Medical Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
DRTS Alpha Tau Medical - reports 100% objective response rate and 18.2-month median overall survival with Alpha dart plus pembrolizumab - No
DRTS Alpha Tau Medical - reports 100% objective response rate and 18.2-month median overall survival with Alpha dart plus pembrolizumab - No serious Alpha dart-associated adverse events; only two grade 1 events reported
EQUITY | Jul 21, 2026, 12:31 PM UTC
M
DRTS: Treats Glioblastoma Patient
Alpha Tau successfully treats first recurrent glioblastoma patient outside of the US with Alpha DaRT at Hadassah University Medical Center in Israel
EQUITY | Jun 23, 2026, 12:30 PM UTC